Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06307340
Other study ID # 22-01058
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date April 2024
Est. completion date October 2025

Study information

Verified date April 2024
Source NYU Langone Health
Contact Brittany Griffin
Phone 646-501-3564
Email Brittany.Griffin@nyulangone.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

During this 36-month R34 trial, eight study phases are proposed to adapt an evidence-based post traumatic stress disorder (PTSD) intervention (STAIR-NT) and layer it into a methadone maintenance treatment (MMT) program (START Treatment and Recovery centers) in New York City for use among individuals engaged in stimulant-opioid polysubstance use. The study aims to adapt STAIR-NT to a massed treatment schedule. Once an adapted protocol is complete, it will be tested for feasibility, acceptability, and short-term polysubstance and PTSD symptomology outcomes in a pilot randomized control trial (RCT) of 80 participants. Participants who screen eligible and consent will be randomized 1:1 to the adapted STAIR-NT intervention or treatment as usual (TAU) using randomization blocks of two and two and four via a computer-generated randomization sequence. Participants assigned to the intervention will receive the adapted massed delivery of STAIR-NT by trained counselors.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 80
Est. completion date October 2025
Est. primary completion date April 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - must be 18 years or older, - be a patient at the START clinic receiving methadone for treatment of opioid use disorder, - self-report 10+ days of co-use of cocaine and illicit opioids in the past 30-days, - meet the criteria for stimulant use disorder (cocaine type; mild, moderate or severe) and a score of 3= on the PC-PTSD-5. Exclusion Criteria: - cognitive impairment that would interfere with their ability to understand study participation as assessed by the researcher, - does not speak/understand English at a conversational level, - plans to leave the START clinic in the next 60 days, - patients who missed methadone doses (inactive) for 30 days or more, or - having received clinical care from the interventionist(s) in the past 30 days

Study Design


Intervention

Behavioral:
Skills Training in Affective and Interpersonal Regulation with Narrative Therapy (STAIR-NT)
Adapted version of evidence-based behavioral PTSD intervention.
Treatment as Usual
Treatment as usual.

Locations

Country Name City State
United States START Treatment and Recovery Centers Brooklyn New York
United States NYU Langone Health New York New York
United States Florida State University Tallahassee Florida

Sponsors (2)

Lead Sponsor Collaborator
NYU Langone Health National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of Eligible Participants Proportion of persons eligible to enroll in the study of all possible MMT patients approached. Assessed using count data of individuals failing screen. Baseline
Primary Proportion of Eligible Participants who Enroll .Proportion of all eligible persons who enroll. Assessed using count data of individuals consented. Baseline
Primary Number of Intervention Sessions Completed Up to Month 3
Primary Clinician-Rated Feasibility of Intervention Measure (FIM) Score 4-item, clinician-rated assessment of the feasibility of the intervention. Each item is rated on a scale from 1 (Completely disagree) to 5 (Completely agree); the total score is the sum of responses and ranges from 4-20. Higher scores indicate greater clinician-rated feasibility. Month 3
Primary Clinician-Rated Feasibility of Acceptability of Intervention Measure (AIM) Score 4-item, clinician-rated assessment of the acceptability of the intervention. Each item is rated on a scale from 1 (Completely disagree) to 5 (Completely agree); the total score is the sum of responses and ranges from 4-20. Higher scores indicate greater clinician-rated acceptability. Month 3
Primary Number of Days of Co-Use of Cocaine and Illicit Opioids Measured using the Addiction Severity Index (ASI) questionnaire. Month 3
Primary Number of Substances Used based on ASI Self-Report Measured using the Addiction Severity Index (ASI) questionnaire, a self-report assessment to gauge the severity of a person's substance abuse. Month 3
Primary Number of Substances Used based on Urine Drug Screen Month 3
Primary Number of Substances Used based on Chart Abstraction of Toxicology Results Month 3
Primary PTSD Checklist for DSM-5 (PCL-5) Score The PCL-5 is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD. Each item is rated on a scale from 0-4. A total symptom severity score (range - 0-80) can be obtained by summing the scores for each of the 20 items; higher scores indicate greater severity of PTSD. Month 3
Primary Negative Mood Regulation Scale Score 30-item assessment of individuals' beliefs and expectations regarding their ability to regulate their negative mood and emotions. Each item is rated on a 5-point Likert scale ranging from 1 (not at all effective) to 5 (extremely effective). The total score ranges from 30-150; higher scores indicate more effective negative mood regulation. Month 3
Primary Inventory of Interpersonal Problems Score A 127-item, self-report inventory that asks participants to rate a variety of interpersonal problems that may cause distress. The items are divided into two groups: (1) interpersonal inadequacies or inhibitions (78 items), (2) excesses or compulsions (49 items). Participants rate each item on a scale from 0 to 4 on how much difficulty/distress they feel regarding the item. The total score is calculated by adding the item responses; lower scores indicate less difficulty/distress. Month 3
See also
  Status Clinical Trial Phase
Completed NCT03384706 - A Comparison of CPT Versus ART Versus WL N/A
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Completed NCT03129204 - Sensation Awareness Focused Training for Spouses N/A
Recruiting NCT05651295 - A Precision Medicine Approach to Target Engagement for Emotion Regulation N/A
Completed NCT05113277 - Development and Evaluation of a Tonic Immobility Focused Psychoeducational Intervention N/A
Recruiting NCT05327504 - Written Exposure Therapy for Veterans With SUD and PTSD N/A
Recruiting NCT05843695 - Enhancing Psychotherapy for Veterans and Service Members With PTSD and Anxiety N/A
Active, not recruiting NCT05530642 - An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel N/A
Completed NCT00644423 - Omega-3 Fatty Acids and Post Traumatic Stress Disorder (PTSD) N/A
Completed NCT02989987 - NET for SGBV Survivors in Eastern DR Congo N/A
Completed NCT02320799 - Randomized Controlled Trial of Interpersonal Psychotherapy for Depression and PTSD Among HIV+ Women in Kenya N/A
Recruiting NCT02293291 - Thermal Clinic Treatment in Gulf War Illness Phase 1/Phase 2
Completed NCT02242136 - Treatment of Posttraumatic Stress Disorder and Aggressive Behavior in Soldiers and Ex-combatants N/A
Completed NCT01911585 - Efficacy of 60-minute Versus 90-minute Sessions in Treating PTSD Using Prolonged Exposure N/A
Completed NCT02720497 - The Efficacy of 90-Minute Versus 60-Minute Sessions of Prolonged Exposure for PTSD N/A
Completed NCT01693978 - Contingency Outcomes in Prolonged Exposure N/A
Terminated NCT01408641 - Topiramate for Alcohol Use in Posttraumatic Stress Disorder N/A
Completed NCT01469754 - Longitudinal Survey Analysis in Lymphoma Survivors N/A
Terminated NCT01239173 - Emotional Memory Reactivation in Posttraumatic Stress Disorder Phase 3
Completed NCT02362477 - Telemental Health and Cognitive Processing Therapy for Female Veterans With Military-related PTSD Phase 3